Provectus Biopharmaceuticals Stock Shares Outstanding
PVCTDelisted Stock | USD 0.11 0.00 0.00% |
Provectus Biopharmaceuticals fundamentals help investors to digest information that contributes to Provectus Biopharmaceutica's financial success or failures. It also enables traders to predict the movement of Provectus OTC Stock. The fundamental analysis module provides a way to measure Provectus Biopharmaceutica's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Provectus Biopharmaceutica otc stock.
Provectus |
Provectus Biopharmaceuticals OTC Stock Shares Outstanding Analysis
Provectus Biopharmaceutica's Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Provectus Biopharmaceutica Shares Outstanding | 419.55 M |
Most of Provectus Biopharmaceutica's fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Provectus Biopharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
CompetitionBased on the latest financial disclosure, Provectus Biopharmaceuticals has 419.55 M of shares currently outstending. This is 132.39% higher than that of the Pharmaceuticals sector and 292.63% higher than that of the Health Care industry. The shares outstanding for all United States stocks is 26.63% higher than that of the company.
Provectus Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Provectus Biopharmaceutica's direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Provectus Biopharmaceutica could also be used in its relative valuation, which is a method of valuing Provectus Biopharmaceutica by comparing valuation metrics of similar companies.Provectus Biopharmaceutica is currently under evaluation in shares outstanding category among related companies.
Provectus Fundamentals
Return On Asset | -1.85 | ||||
Operating Margin | (4.77) % | ||||
Current Valuation | 46.73 M | ||||
Shares Outstanding | 419.55 M | ||||
Shares Owned By Insiders | 3.69 % | ||||
Shares Owned By Institutions | 0.04 % | ||||
Number Of Shares Shorted | 1.82 M | ||||
Price To Earning | (0.48) X | ||||
Price To Book | 5.44 X | ||||
Price To Sales | 55.94 X | ||||
EBITDA | (4.56 M) | ||||
Net Income | (5.54 M) | ||||
Cash And Equivalents | 84.27 K | ||||
Total Debt | 2.29 M | ||||
Debt To Equity | 0.25 % | ||||
Current Ratio | 0.27 X | ||||
Book Value Per Share | (0.02) X | ||||
Cash Flow From Operations | (1.01 M) | ||||
Short Ratio | 0.47 X | ||||
Earnings Per Share | (0.01) X | ||||
Target Price | 3.5 | ||||
Beta | 0.5 | ||||
Market Capitalization | 44.47 M | ||||
Total Asset | 3.51 M | ||||
Retained Earnings | (180.8 M) | ||||
Working Capital | 10.6 M | ||||
Current Asset | 14.72 M | ||||
Current Liabilities | 4.12 M | ||||
Z Score | -59.7 | ||||
Net Asset | 3.51 M |
About Provectus Biopharmaceutica Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Provectus Biopharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Provectus Biopharmaceutica using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Provectus Biopharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Provectus Biopharmaceutica using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Provectus Biopharmaceutica information on this page should be used as a complementary analysis to other Provectus Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Other Consideration for investing in Provectus OTC Stock
If you are still planning to invest in Provectus Biopharmaceutica check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Provectus Biopharmaceutica's history and understand the potential risks before investing.
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
CEOs Directory Screen CEOs from public companies around the world | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets |